Is triple negative a prognostic factor in breast cancer? View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-03-29

AUTHORS

Reiki Nishimura, Nobuyuki Arima

ABSTRACT

BackgroundBreast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.Patients and methodsBetween January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.ResultsPatient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.ConclusionTN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed. More... »

PAGES

303-308

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3

DOI

http://dx.doi.org/10.1007/s12282-008-0042-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000535344

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18369692


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Reiki", 
        "id": "sg:person.013173055502.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arima", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.016542450374.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/35021093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033846543", 
          "https://doi.org/10.1038/35021093"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-005-0010-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048189318", 
          "https://doi.org/10.1007/s00428-005-0010-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-006-0601-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001769831", 
          "https://doi.org/10.1007/s10147-006-0601-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2325/jbcs.13.232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018645053", 
          "https://doi.org/10.2325/jbcs.13.232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02967579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049185654", 
          "https://doi.org/10.1007/bf02967579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12282-007-0014-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017336968", 
          "https://doi.org/10.1007/s12282-007-0014-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-03-29", 
    "datePublishedReg": "2008-03-29", 
    "description": "BackgroundBreast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.Patients and methodsBetween January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.ResultsPatient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.ConclusionTN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12282-008-0042-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1021080", 
        "issn": [
          "1340-6868", 
          "1880-4233"
        ], 
        "name": "Breast Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "disease-free survival", 
      "TN breast cancer", 
      "high nuclear grade", 
      "breast cancer", 
      "estrogen receptor", 
      "HER2 status", 
      "p53 overexpression", 
      "nuclear grade", 
      "high proliferation rate", 
      "HER2-positive breast cancer", 
      "poor disease-free survival", 
      "triple-negative breast cancer", 
      "non-TN tumors", 
      "overall survival rate", 
      "primary breast cancer", 
      "HER2 protein overexpression", 
      "frequent p53 overexpression", 
      "proliferation rate", 
      "endocrine therapy", 
      "prognostic factors", 
      "trastuzumab treatment", 
      "prognostic characteristics", 
      "rare subtype", 
      "hormone dependency", 
      "progesterone receptor", 
      "TN tumors", 
      "BackgroundBreast cancer", 
      "targeted therapy", 
      "Ki67 values", 
      "lack of expression", 
      "key treatment", 
      "survival rate", 
      "TN cases", 
      "multivariate analysis", 
      "cancer", 
      "patients", 
      "ResultsPatient distribution", 
      "therapy", 
      "protein overexpression", 
      "recurrence", 
      "new effective strategy", 
      "PgR", 
      "tumors", 
      "subtypes", 
      "receptors", 
      "overexpression", 
      "treatment", 
      "status", 
      "effective strategy", 
      "significant factor", 
      "OS", 
      "grade", 
      "prognosis", 
      "HER2", 
      "cases", 
      "survival", 
      "rate", 
      "factors", 
      "study", 
      "expression", 
      "absence", 
      "lack", 
      "regard", 
      "strategies", 
      "analysis", 
      "characteristics", 
      "values", 
      "distribution", 
      "dependency", 
      "TN"
    ], 
    "name": "Is triple negative a prognostic factor in breast cancer?", 
    "pagination": "303-308", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000535344"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12282-008-0042-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18369692"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12282-008-0042-3", 
      "https://app.dimensions.ai/details/publication/pub.1000535344"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_457.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12282-008-0042-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12282-008-0042-3'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      22 PREDICATES      123 URIs      109 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12282-008-0042-3 schema:about N11d370013e04409488a8ed68786ad935
2 N12d96495e2614b94a4fe19df62e0c004
3 N1412c2bf4c5246d3803b93badd09d3d5
4 N24c6df5efd15468aa93ba47fa33af095
5 N341f71714cfc4e3b94651c24fd5d58e9
6 N413cc3cf98af42d3a19a942f93aa703c
7 N42a13f4baaca436ea406344280d91305
8 N46e837b5fe4343698267064a57f71551
9 N48cf86acec674e62ac8fac7a14f4537c
10 N554c7c7b7c1142a3a91cf5f91b3c5273
11 N5b776694f48a47879d416fac8281c648
12 N5ed29b19459148dcb74315a8411a5f1e
13 N5fdc607f5e294166aaa206268a27bcb7
14 N95dfca665da945a8b8cb232776b8d111
15 Nc9c1842427754c3aab2332ecbc133188
16 Ncf1fbc384cdb46e6974887ff0eddc580
17 Nd4f674845ffc4676a275b9a31c07971f
18 Nd70b0391a9744abf959bb81ca48fc570
19 Ne9406156c9734e0eb595c651eebb2f97
20 Neb3608af30e64fe58f1f5c6ad4cfbc58
21 Nfbb1f54746f74d0194e81664253ac227
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N958726a6c0844ca7bd98f67b6837fbe9
25 schema:citation sg:pub.10.1007/bf02967579
26 sg:pub.10.1007/s00428-005-0010-7
27 sg:pub.10.1007/s10147-006-0601-6
28 sg:pub.10.1007/s12282-007-0014-z
29 sg:pub.10.1038/35021093
30 sg:pub.10.2325/jbcs.13.232
31 schema:datePublished 2008-03-29
32 schema:datePublishedReg 2008-03-29
33 schema:description BackgroundBreast cancer is characterized by hormone dependency, and endocrine therapy is a key treatment in breast cancer. Recently, targeted therapies such as Trastuzumab treatment for HER2-positive breast cancer has been important. Triple-negative (TN) breast cancer is characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and the absence of HER2 protein overexpression, and so there is no targeted therapy for this subtype. In this study, we examined the biological and prognostic characteristics in TN breast cancer.Patients and methodsBetween January 1998 and September 2006, 1,552 patients with primary breast cancer were investigated retrospectively in this study and ER, PgR and HER2 status were evaluated in all cases. Furthermore, p53 overexpression and Ki67 values were examined immunohistochemically.ResultsPatient distribution according to ER, PgR or HER2 status was as follows: ER and PgR positive: 57.9%, and ER and PgR negative: 25.1%. With regards to the HER2 status, HER2 positive was 23.3%, and triple negative (TN) was 14.0%. TN breast cancer has a high proliferation rate, high nuclear grade and frequent p53 overexpression. Patients with TN tumors had a significantly poorer disease-free survival (DFS) than those with non-TN tumors. After recurrence the overall survival (OS) rate in TN cases was significantly lower than that of the non-TN cases. Multivariate analysis revealed that TN was a significant factor for DFS and OS after recurrence.ConclusionTN breast cancer is a rare subtype with a high proliferation rate and a high nuclear grade, p53 overexpression, and lower DFS/OS. To improve the prognosis of TN breast cancer, a new effective strategy needs to be developed.
34 schema:genre article
35 schema:inLanguage en
36 schema:isAccessibleForFree false
37 schema:isPartOf N835fc15a63b247d0b44a84ff729a9988
38 Nfa3445ad5ad0478387d1e92ca2119d97
39 sg:journal.1021080
40 schema:keywords BackgroundBreast cancer
41 HER2
42 HER2 protein overexpression
43 HER2 status
44 HER2-positive breast cancer
45 Ki67 values
46 OS
47 PgR
48 ResultsPatient distribution
49 TN
50 TN breast cancer
51 TN cases
52 TN tumors
53 absence
54 analysis
55 breast cancer
56 cancer
57 cases
58 characteristics
59 dependency
60 disease-free survival
61 distribution
62 effective strategy
63 endocrine therapy
64 estrogen receptor
65 expression
66 factors
67 frequent p53 overexpression
68 grade
69 high nuclear grade
70 high proliferation rate
71 hormone dependency
72 key treatment
73 lack
74 lack of expression
75 multivariate analysis
76 new effective strategy
77 non-TN tumors
78 nuclear grade
79 overall survival rate
80 overexpression
81 p53 overexpression
82 patients
83 poor disease-free survival
84 primary breast cancer
85 progesterone receptor
86 prognosis
87 prognostic characteristics
88 prognostic factors
89 proliferation rate
90 protein overexpression
91 rare subtype
92 rate
93 receptors
94 recurrence
95 regard
96 significant factor
97 status
98 strategies
99 study
100 subtypes
101 survival
102 survival rate
103 targeted therapy
104 therapy
105 trastuzumab treatment
106 treatment
107 triple-negative breast cancer
108 tumors
109 values
110 schema:name Is triple negative a prognostic factor in breast cancer?
111 schema:pagination 303-308
112 schema:productId N44601d638e2844d6928d9bb24385e5d2
113 Nb676ac0ffceb4084a3b8cc61331643f5
114 Nd6db451a058442979af03eca65ded12c
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000535344
116 https://doi.org/10.1007/s12282-008-0042-3
117 schema:sdDatePublished 2022-06-01T22:07
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Nd2d0a9b6f6fa4591a67d29a486c51cba
120 schema:url https://doi.org/10.1007/s12282-008-0042-3
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N11d370013e04409488a8ed68786ad935 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Phenotype
126 rdf:type schema:DefinedTerm
127 N12d96495e2614b94a4fe19df62e0c004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Antineoplastic Agents
129 rdf:type schema:DefinedTerm
130 N1412c2bf4c5246d3803b93badd09d3d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Cell Proliferation
132 rdf:type schema:DefinedTerm
133 N24c6df5efd15468aa93ba47fa33af095 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Adult
135 rdf:type schema:DefinedTerm
136 N341f71714cfc4e3b94651c24fd5d58e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Neoplasm Staging
138 rdf:type schema:DefinedTerm
139 N413cc3cf98af42d3a19a942f93aa703c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Receptor, ErbB-2
141 rdf:type schema:DefinedTerm
142 N42a13f4baaca436ea406344280d91305 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Treatment Outcome
144 rdf:type schema:DefinedTerm
145 N44601d638e2844d6928d9bb24385e5d2 schema:name doi
146 schema:value 10.1007/s12282-008-0042-3
147 rdf:type schema:PropertyValue
148 N46e837b5fe4343698267064a57f71551 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Receptors, Progesterone
150 rdf:type schema:DefinedTerm
151 N48cf86acec674e62ac8fac7a14f4537c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged
153 rdf:type schema:DefinedTerm
154 N554c7c7b7c1142a3a91cf5f91b3c5273 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Female
156 rdf:type schema:DefinedTerm
157 N5b776694f48a47879d416fac8281c648 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Immunoenzyme Techniques
159 rdf:type schema:DefinedTerm
160 N5ed29b19459148dcb74315a8411a5f1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Breast Neoplasms
162 rdf:type schema:DefinedTerm
163 N5fdc607f5e294166aaa206268a27bcb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Humans
165 rdf:type schema:DefinedTerm
166 N835fc15a63b247d0b44a84ff729a9988 schema:volumeNumber 15
167 rdf:type schema:PublicationVolume
168 N958726a6c0844ca7bd98f67b6837fbe9 rdf:first sg:person.013173055502.44
169 rdf:rest Nc5dadc680d3b4c60b24295cda64f4314
170 N95dfca665da945a8b8cb232776b8d111 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Prognosis
172 rdf:type schema:DefinedTerm
173 Nb676ac0ffceb4084a3b8cc61331643f5 schema:name dimensions_id
174 schema:value pub.1000535344
175 rdf:type schema:PropertyValue
176 Nc5dadc680d3b4c60b24295cda64f4314 rdf:first sg:person.016542450374.76
177 rdf:rest rdf:nil
178 Nc9c1842427754c3aab2332ecbc133188 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Survival Rate
180 rdf:type schema:DefinedTerm
181 Ncf1fbc384cdb46e6974887ff0eddc580 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Aged, 80 and over
183 rdf:type schema:DefinedTerm
184 Nd2d0a9b6f6fa4591a67d29a486c51cba schema:name Springer Nature - SN SciGraph project
185 rdf:type schema:Organization
186 Nd4f674845ffc4676a275b9a31c07971f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Biomarkers, Tumor
188 rdf:type schema:DefinedTerm
189 Nd6db451a058442979af03eca65ded12c schema:name pubmed_id
190 schema:value 18369692
191 rdf:type schema:PropertyValue
192 Nd70b0391a9744abf959bb81ca48fc570 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Middle Aged
194 rdf:type schema:DefinedTerm
195 Ne9406156c9734e0eb595c651eebb2f97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Receptors, Estrogen
197 rdf:type schema:DefinedTerm
198 Neb3608af30e64fe58f1f5c6ad4cfbc58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Tumor Suppressor Protein p53
200 rdf:type schema:DefinedTerm
201 Nfa3445ad5ad0478387d1e92ca2119d97 schema:issueNumber 4
202 rdf:type schema:PublicationIssue
203 Nfbb1f54746f74d0194e81664253ac227 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Retrospective Studies
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
210 schema:name Oncology and Carcinogenesis
211 rdf:type schema:DefinedTerm
212 sg:journal.1021080 schema:issn 1340-6868
213 1880-4233
214 schema:name Breast Cancer
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.013173055502.44 schema:affiliation grid-institutes:grid.415532.4
218 schema:familyName Nishimura
219 schema:givenName Reiki
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44
221 rdf:type schema:Person
222 sg:person.016542450374.76 schema:affiliation grid-institutes:grid.415532.4
223 schema:familyName Arima
224 schema:givenName Nobuyuki
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76
226 rdf:type schema:Person
227 sg:pub.10.1007/bf02967579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049185654
228 https://doi.org/10.1007/bf02967579
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s00428-005-0010-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048189318
231 https://doi.org/10.1007/s00428-005-0010-7
232 rdf:type schema:CreativeWork
233 sg:pub.10.1007/s10147-006-0601-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001769831
234 https://doi.org/10.1007/s10147-006-0601-6
235 rdf:type schema:CreativeWork
236 sg:pub.10.1007/s12282-007-0014-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1017336968
237 https://doi.org/10.1007/s12282-007-0014-z
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/35021093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033846543
240 https://doi.org/10.1038/35021093
241 rdf:type schema:CreativeWork
242 sg:pub.10.2325/jbcs.13.232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018645053
243 https://doi.org/10.2325/jbcs.13.232
244 rdf:type schema:CreativeWork
245 grid-institutes:grid.415532.4 schema:alternateName Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan
246 Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan
247 schema:name Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan
248 Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...